Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3116816 | 0.84 | GAA (0.35) | GAA | |
| SCHEMBL28760707 | 0.83 | MEN1 (0.35) | GAA | |
| SCHEMBL4199230 | 0.81 | BRD9 (0.36) | — | |
| SCHEMBL28760706 | 0.78 | ALDH1A1 (0.36) | GAA | |
| SCHEMBL6065935 | 0.78 | GAA (0.35) | GAA | |
| SCHEMBL6065937 | 0.78 | GAA (0.35) | GAA | |
| SCHEMBL6065967 | 0.78 | ACSS2 (0.33) | GAA | |
| Carbamic Acid SCHEMBL3119184 | 0.77 | BRD4 (0.32) | GAA | |
| Carbamic Acid SCHEMBL3119239 | 0.77 | BRD4 (0.32) | GAA | |
| SCHEMBL27641140 | 0.77 | ACSS2 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1556389-B9 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2015-09-09 | — | — | EP | disclosed |
| EP-1556389-B3 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2015-04-01 | — | — | EP | disclosed |
| US-20090012054-A1 | Cephem Compounds and Use as Antimicrobial Agents | ASTELLAS PHARMA INC. (JP) | 2009-01-08 | — | — | US | disclosed |
| EP-1994035-A1 | CEPHEM COMPOUNDS AND USE AS ANTIMICROBIAL AGENTS | Astellas Pharma Inc. (JP) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007119511-A1 | CEPHEM COMPOUNDS AND USE AS ANTIMICROBIAL AGENTS | ASTELLAS PHARMA INC. (JP) | 2007-10-25 | — | — | WO | disclosed |
| EP-1556389-B1 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2007-07-25 | — | — | EP | disclosed |
| US-20070037786-A1 | Cephem compounds | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2007-02-15 | — | — | US | disclosed |
| US-7129232-B2 | For therapy of of infectious diseases | ASTELLAS PHARMA INC. (JP) | 2006-10-31 | — | — | US | disclosed |
| EP-1556389-A1 | CEPHEM COMPOUNDS | Astellas Pharma Inc. (JP) | 2005-07-27 | — | — | EP | disclosed |
| US-20040132994-A1 | Cephem compounds | FUJISAWA PHARMACEUTICAL CO., LTD (JP) | 2004-07-08 | — | — | US | disclosed |
| WO-2004039814-A1 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037786-A1 | Cephem compounds | CEP170, ABCB11, SLC7A1 | GAA 3656/4885 |
| US-20040132994-A1 | Cephem compounds | CEP170, ABCB11, RCC2 | GAA 3832/4885 |
| US-20090012054-A1 | Cephem Compounds and Use as Antimicrobial Agents | CEP170, Q6ZSR9, H1-10 | GAA 4701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.